CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
Placebo oral tablet +2 moredrug
Likely dose
Simufilam 100 mg tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04079803
NCT04079803Phase 2Completed
CompareCT.gov

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of PTI-125 in Mild-to-moderate Alzheimer's Disease Patients

Cassava Sciences, Inc.·interventional·Posted Sep 6, 2019·Updated Sep 29, 2021

In Brief

A Phase 2 clinical trial evaluating Placebo oral tablet, Simufilam 100 mg tablet, and 1 other intervention for Alzheimer Disease. Completed, enrolled 64 participants across 9 sites.

Detailed Summary

This is a Phase 2b, Randomized, Double-blind, Placebo-controlled, multiple dose study of PTI-125 in mild-to-moderate Alzheimer's disease patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 6, 2019
Enrollment StartSep 9, 2019
Primary CompletionMar 31, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.8 years ago

Interventions

Placebo oral tabletdrug

Oral placebo tablet

Simufilam 100 mg tabletdrug

Simufilam 100 mg oral tablet

Simufilam 50 mg oral tabletdrug

Simufilam 50 mg oral tablet